{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:08Z","timestamp":1790089628178,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Prevention and Research Institute of Texas Clinical Trial Network Award","award":["RP220542"],"award-info":[{"award-number":["RP220542"]}],"id":[{"id":"https:\/\/ror.org\/0003xa228","id-type":"ROR","asserted-by":"crossref"}]},{"name":"JPS Health Network","id":[{"id":"https:\/\/ror.org\/02nkp4593","id-type":"ROR","asserted-by":"crossref"}]},{"name":"EMBER-4 Clinical Trial"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Racial and ethnic inequities persist in oncology clinical trial participation, while safety-net health systems may face resource and data limitations that complicate candidate identification. We evaluated the feasibility of an electronic health record (EHR)-assisted prescreening workflow for EMBER-4, a phase 3 adjuvant breast cancer trial, at a safety-net health system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Structured Query Language (SQL) queries applied to Epic Clarity identified potential candidates using diagnosis codes, receptor-status codes, endocrine therapy medication records, recent oncology follow-up, and appointment data. Research staff then manually reviewed pathology reports, treatment history, comorbidities, and other protocol criteria to determine full eligibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The source population with a diagnosis of breast cancer included 829 patients: 29% Hispanic, 30% Black, 31% non-Hispanic White, and 9.7% others. Primary language was English in 75% and Spanish in 18%. The SQL query identified 123 potential candidates; manual review confirmed 18 eligible patients comprising 67% Hispanic and 44% Spanish language, yielding a positive predictive value of 15%. Clinicians identified 3 additional eligible patients missed by the query, for 21 known eligible patients overall. Eleven declined participation, one did not attend the scheduled clinic visit, and 9 consented. One patient withdrew before randomization and 8 were enrolled. Six enrolled patients were Hispanic, 1 was non-Hispanic White and 1 was Black.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a safety-net oncology setting, her-assisted prescreening was feasible but required manual verification and clinician involvement. The workflow identified most known eligible patients, although incomplete structured data and low positive predictive value limited its utility as a standalone screening method.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag339","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:20:47Z","timestamp":1788186047000},"source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of EHR-based prescreening for an adjuvant breast cancer trial in a safety-net health system"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-229X","authenticated-orcid":false,"given":"Hussain","family":"Alkhafaji","sequence":"first","affiliation":[{"name":"University of Texas Southwestern Medical School , Dallas, TX 75390,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay C K","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Office of Clinical Research, JPS Health Network , Fort Worth, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Howell","sequence":"additional","affiliation":[{"name":"IT Business Intelligence, JPS Health Network , Fort Worth, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D","family":"Henderson","sequence":"additional","affiliation":[{"name":"IT Business Intelligence, JPS Health Network , Fort Worth, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedra","family":"Preece","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Medical Center , Temple, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-2175","authenticated-orcid":false,"given":"Kari J","family":"Teigen","sequence":"additional","affiliation":[{"name":"Office of Clinical Research, JPS Health Network , Fort Worth, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-6741","authenticated-orcid":false,"given":"David E","family":"Gerber","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]},{"name":"Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]},{"name":"Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas , TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4443-6457","authenticated-orcid":false,"given":"Kalyani","family":"Narra","sequence":"additional","affiliation":[{"name":"JPS Oncology and Infusion Center , Fort Worth, TX,","place":["United States"]},{"name":"Burnett School of Medicine, Texas Christian University , Fort Worth, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026092210523862300_oyag339-B1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026092210523862300_oyag339-B2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jadpro.2022.13.8.2","article-title":"Inclusion of racial and ethnic minorities in cancer clinical trials: 30 years after the NIH Revitalization Act, where are we?","volume":"13","author":"Mutale","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"2026092210523862300_oyag339-B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","article-title":"Representation of minorities and women in oncology clinical trials: review of the past 14 years","volume":"14","author":"Duma","year":"2018","journal-title":"J Oncol Pract"},{"key":"2026092210523862300_oyag339-B4","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"2026092210523862300_oyag339-B5","doi-asserted-by":"publisher","first-page":"e2322515","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026092210523862300_oyag339-B6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2026092210523862300_oyag339-B7","doi-asserted-by":"publisher","first-page":"e2322436","DOI":"10.1001\/jamanetworkopen.2023.22436","article-title":"A ground\u2019s-eye view on racial and ethnic disparities in cancer clinical trial participation","volume":"6","author":"Unger","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026092210523862300_oyag339-B8","author":"U.S. Food and Drug Administration"},{"key":"2026092210523862300_oyag339-B9","author":"U.S. Food and Drug Administration"},{"key":"2026092210523862300_oyag339-B10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cct.2009.06.009","article-title":"Recruiting minorities where they receive care: institutional barriers to cancer clinical trials recruitment in a safety-net hospital","volume":"30","author":"Joseph","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"2026092210523862300_oyag339-B11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11606-023-08489-6","article-title":"Greater investments in safety net health systems can help diversify participation in clinical trials and research","volume":"39","author":"Coronado","year":"2024","journal-title":"J Gen Intern Med"},{"key":"2026092210523862300_oyag339-B12","doi-asserted-by":"publisher","first-page":"e0313530","DOI":"10.1371\/journal.pone.0313530","article-title":"Barriers and facilitators to conducting human subjects research at a safety net institution from the perspective of researchers","volume":"20","author":"Barnes","year":"2025","journal-title":"PLoS One"},{"key":"2026092210523862300_oyag339-B13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1634\/theoncologist.2015-0083","article-title":"Temporal trends and predictors for cancer clinical trial availability for medically underserved populations","volume":"20","author":"Gerber","year":"2015","journal-title":"Oncologist"},{"key":"2026092210523862300_oyag339-B14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"key":"2026092210523862300_oyag339-B15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/jamaoncol.2021.1165","article-title":"Application of information technology to clinical trial evaluation and enrollment: a review","volume":"7","author":"von Itzstein","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026092210523862300_oyag339-B16","doi-asserted-by":"publisher","first-page":"20552076241242390","DOI":"10.1177\/20552076241242390","article-title":"Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: a systematic review","volume":"10","author":"Kasahara","year":"2024","journal-title":"Digit Health"},{"key":"2026092210523862300_oyag339-B17","author":"Tarrant County Hospital District\/JPS Health Network","year":"2020"},{"key":"2026092210523862300_oyag339-B18","author":"U.S. Census Bureau"},{"key":"2026092210523862300_oyag339-B19","author":"JPS Health Network","year":"2023"},{"key":"2026092210523862300_oyag339-B20","author":"Cancer Prevention and Research Institute of Texas","year":"2022"},{"key":"2026092210523862300_oyag339-B21","author":"ClinicalTrials.gov"},{"key":"2026092210523862300_oyag339-B22","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients\u2019 decision making on participation in clinical trials","volume":"26","author":"Albrecht","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026092210523862300_oyag339-B23","article-title":"Misconceptions and lack of awareness greatly reduce recruitment for cancer clinical trials","volume":"1","author":"Harris Interactive","year":"2001","journal-title":"Health Care News"},{"key":"2026092210523862300_oyag339-B24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2003.02.105","article-title":"Public attitudes toward participation in cancer clinical trials","volume":"21","author":"Comis","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026092210523862300_oyag339-B25","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.mayocp.2023.05.003","article-title":"Health disparities, clinical trials, and the digital divide","volume":"98","author":"Adedinsewo","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2026092210523862300_oyag339-B26","doi-asserted-by":"publisher","first-page":"1483367","DOI":"10.3389\/fpubh.2024.1483367","article-title":"Leveraging digital tools to enhance diversity and inclusion in clinical trial recruitment","volume":"12","author":"Tomiwa","year":"2024","journal-title":"Front Public Health"},{"key":"2026092210523862300_oyag339-B27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13063-024-07918-z","article-title":"Effectiveness of IT-supported patient recruitment: study protocol for an interrupted time series study at ten German university hospitals","volume":"25","author":"Boeker","year":"2024","journal-title":"Trials"},{"key":"2026092210523862300_oyag339-B28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamaoncol.2023.6565","article-title":"Decentralized clinical trials as a new paradigm of trial delivery to improve equity of access","volume":"10","author":"Underhill","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026092210523862300_oyag339-B29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1200\/CCI.19.00079","article-title":"Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center","volume":"4","author":"Beck","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"2026092210523862300_oyag339-B30","doi-asserted-by":"publisher","first-page":"e27767","DOI":"10.2196\/27767","article-title":"Accuracy of an artificial intelligence system for cancer clinical trial eligibility screening: retrospective pilot study","volume":"9","author":"Haddad","year":"2021","journal-title":"JMIR Med Inform"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag339\/70883212\/oyag339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag339\/70883212\/oyag339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag339\/70883212\/oyag339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:43Z","timestamp":1790088763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag339\/8776811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag339","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"oyag339"}}